ASE Technology Holding Co Ltd vs BIO-TECHNE Corp — how do they compare? ASE Technology Holding Co Ltd trades at $41.42 (market cap $91.92B), while BIO-TECHNE Corp trades at $71.23 (market cap $11.12B). The key difference: ASE Technology Holding Co Ltd is far larger — about 8.3× BIO-TECHNE Corp's market cap, and ASE Technology Holding Co Ltd pays the higher dividend (1.03%). Which is the better fit depends on your goals.
| ASX | TECH | |
|---|---|---|
Market Cap | $91.92B | $11.12B |
Sector | Technology | Health |
52-Week High | $45.12 | $71.38 |
52-Week Low | $9.50 | $43.31 |
Enterprise Value | $96.36B | $11.20B |
Dividend Yield | 1.03% | 0.45% |
Signals from Pluang's Aura AI — not financial advice
ASE Technology Holding (ASX) trades at $40.56, down 4.92% over 24 hours, with a neutral technical signal. The company shows strong earnings momentum with three consecutive quarterly beats and robust cash flow growth. Revenue reached $645.39B in 2025 with net income of $40.02B, while analyst sentiment remains positive with 80% buy ratings. Recent news highlights AI-driven packaging demand and LEAP business growth exceeding $3.5B in 2026 revenue outlook.
The stock presents growth potential from AI infrastructure demand and margin expansion, though elevated P/E ratio of 63.65 suggests premium valuation. Key risks include semiconductor cycle volatility and execution challenges in scaling advanced packaging capacity. Institutional ownership trends and positive earnings revisions support the bullish case, but investors should monitor competitive pressures in the semiconductor packaging sector.
No Aura AI signal available yet.
Trailing returns across standard periods
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.
Read more on ASX →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →